Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Selective Inhibitors of Polo-like Kinase 1 (PLK1) Polo-box Domains as Potential Anticancer Agents

Posted Feb 12 2012 7:00pm

Description of Invention:
PLK1 is a regulator of cell growth that represents a new target for anticancer therapeutic development. High expression of PLK1 has been associated with several types of cancer (e.g., breast cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma). Inhibiting PLK1 could be an effective treatment for cancer patients without significant side-effects. Available for licensing are synthetic peptides with the ability to bind to polo-like kinase 1 (PLK1) polo-box domains (PBDs) with selectivity and nanomolar affinity and induce apoptosis in cancer cells. By inhibiting the functions of PLK1, these peptides could serve as potential anti-cancer therapies. This technology is related to and an extension of HHS technology reference E-181-2009.

Applications:
  • New anticancer therapies that specifically target PLK1.
  • Platform for the development of further improved PLK1 inhibitors.


Advantages:
  • High PBD binding affinity
  • High binding selectivity


Development Status:
Early-stage

Inventors:
Terrence R Burke (NCI)


Patent Status:
HHS, Reference No. E-053-2012/0
US, Application No. 61/588,470 filed 19 Jan 2012


Related Technologies:
US, Application No. 61/474,621 filed 12 Apr 2011, Reference No. E-181-2009/3


Relevant Publication:
  1. Liu F, et al. [ PMID 21765407 ]
  2. Qian W, et al. [ PMID 21950469 ]



For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 2364

Updated: 02/2012

Post a comment
Write a comment:

Related Searches